In the last trading session, 93277.0 Third Harmonic Bio Inc (NASDAQ:THRD) shares changed hands as the company’s beta touched 2.74. With the company’s per share price at $10.32 changed hands at -$0.48 or -4.44% during last session, the market valuation stood at $465.00M. THRD’s last price was a discount, traded about -64.15% off its 52-week high of $16.94. The share price had its 52-week low at $8.07, which suggests the last value was 21.8% up since then. When we look at Third Harmonic Bio Inc’s average trading volume, we note the 10-day average is 0.19 million shares, with the 3-month average coming to 194.31K.
Analysts gave the Third Harmonic Bio Inc (THRD) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.25. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended THRD as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Third Harmonic Bio Inc’s EPS for the current quarter is expected to be -0.37.
Third Harmonic Bio Inc (NASDAQ:THRD) trade information
Instantly THRD was in red as seen at the end of in last trading. With action -9.07%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -5.93%, with the 5-day performance at -9.07% in the red. However, in the 30-day time frame, Third Harmonic Bio Inc (NASDAQ:THRD) is -17.24% down. Looking at the short shares, we see there were 3.06 million shares sold at short interest cover period of 10.8 days.
The consensus price target for the stock as assigned by Wall Street analysts is 20, meaning bulls need an upside of 48.4% from its current market value. According to analyst projections, THRD’s forecast low is 20 with 20 as the target high. To hit the forecast high, the stock’s price needs a -93.8% plunge from its current level, while the stock would need to soar -93.8% for it to hit the projected low.
Third Harmonic Bio Inc (THRD) estimates and forecasts
Data shows that the Third Harmonic Bio Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -17.77% over the past 6 months, a -42.31% in annual growth rate that is considerably lower than the industry average of 16.70%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
The 2024 estimates are for Third Harmonic Bio Inc earnings to decrease by -41.99%.
THRD Dividends
Third Harmonic Bio Inc is expected to release its next quarterly earnings report in January.
Third Harmonic Bio Inc (NASDAQ:THRD)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 9.05% of Third Harmonic Bio Inc shares while 92.38% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 101.57%. There are 92.38% institutions holding the Third Harmonic Bio Inc stock share, with ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC the top institutional holder. As of 2024-06-30, the company held 26.8961% of the shares, roughly 10.91 million THRD shares worth $141.8 million.
ORBIMED ADVISORS LLC holds the second largest percentage of outstanding shares, with 14.2498% or 5.78 million shares worth $75.13 million as of 2024-06-30.
